The competition prompts them to snap up promising products...

The competition prompts them to snap up promising products earlier in the development cycle. Australian science is pretty well regarded world-wide, and Dendreon helps with acceptance and, in that respect, to some degree a little de-risking of the concept, if not the specific product.

With senior ex-big pharma employees added to Prima, it must help raise their profile in the industry - where it counts, if takeover is what you hope for with PRR.

More broadly speaking, good to see PRR price being sustained with so much volume. The sheer level of interest and the price dynamic that ongoing interest can generate increases the chances of a fundamental re-rating.

The certainty of the FDA trial now makes a lot of difference to most investors. It is one thing for us to find the approval pretty much as expected, but those less familiar with the progress prior to that event will rightly find it more significant.

Indeed, it is very significant, and I expect some posters tend to discount the significance a bit through already being confident that it would occur.